Downstream of downstream processing: Development of recycling strategies for biopharmaceutical processes

Journal of Chemical Technology and Biotechnology

Volumn 87, Issue 4, 2012, Pages 481-497

  Grote, Florian ^a   Ditz, Reinhard ^b   Strube, Jochen ^a  

^a CLAUSTHAL UNIVERSITY OF TECHNOLOGY   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

Biotechnology; Downstream; Membrane technology; Modelling; Recycling; Sustainability

Indexed keywords

AUXILIARY MATERIALS; BIO-PRODUCTION; BIOPHARMACEUTICAL PRODUCTS; BIOPROCESSES; BIOTECHNOLOGICAL PRODUCTION; DESIGN AND OPTIMIZATION; DOWNSTREAM; DOWNSTREAM-PROCESSING; EXPERIMENTAL MODELS; FULL INTEGRATION; INTEGRATED PROCESS; MODELLING; MULTI-STEP; PROCESS DEVELOPMENT; PROCESS ENVIRONMENT; PRODUCT CONCENTRATION; RECYCLING STRATEGY; SINGLE-STEP; SMALL SCALE; STEPWISE APPROACH;

BIOTECHNOLOGY; CHEMICAL OPERATIONS; MEMBRANE TECHNOLOGY; PRODUCT DEVELOPMENT; RECYCLING; SUSTAINABLE DEVELOPMENT;

PRODUCT DESIGN;

DRINKING WATER; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; BIOCOMPATIBILITY; BIOMASS; BIOSAFETY; BIOTECHNOLOGY; CONCEPTUAL FRAMEWORK; CONTAMINATION; COST EFFECTIVENESS ANALYSIS; DESALINATION; EVAPORATION; EXPERIMENTAL MODEL; GEL PERMEATION CHROMATOGRAPHY; GOOD MANUFACTURING PRACTICE; METHODOLOGY; MOLECULAR SIZE; PRESSURE; PURIFICATION; RECYCLING; REVERSE OSMOSIS; SEPARATION TECHNIQUE; SIMULATION; ULTRAFILTRATION; WASTE WATER MANAGEMENT;

EID: 84858289785     PISSN: 02682575     EISSN: 10974660     Source Type: Journal    
DOI: 10.1002/jctb.2727     Document Type: Article

References (78)

1. Jagschies G, Where is biopharmaceutical manufacturing heading? BioPharm Int October: 72-82 (2008).
2. Sommerfeld S and Strube J, Challenges in production of therapeutical biologicals. Chem Eng Process 44: 1123-1137 (2005).
3. Hubbuch J, Karau A and Kaiser K, Engpass downstream processing, transkript Nr. 10, 13. Jahrgang (2007).
4. DePalma A, Levelling downstream process bottlenecks. Genetic Eng Biotechnol News 30: 9 (2010).
5. Winkelnkemper T and Schembecker G, Purification fingerprints for experimentally based systematic downstream process development. Sep Purif Technol 71: 356-366 (2010).
6. Nfor B, Ahamed T, van Dedem G, van der Wielen L, van de Sandt E, Eppnik M et al, Design strategies for integrated protein purification processes: challenges, progress and outlook. J Chem Technol Biotechnol 83: 124-132 (2008).
7. Behrendt U, Frech C, Hubbuch J, Müller E, Scriba A and Wrba A. In Protein Purification-Quo Vadis? Tutzing, Germany (2007).
8. Langer E, Executives at nearly 450 global drug manufacturers weigh in on what's troubling them now, and what challenges face them ahead (2009)..
9. Reutner U, Wege durch die Bottlenecks der Biotech Produktion. P&A 7: 16 (2007).
10. Hedhammar M, Graslund T and Hober S, Protein engineering strategies for selective protein purification. Chem Eng Technol 28: 1315-1325 (2005).
11. Strube J, Sommerfeld S and Lohrmann M, Processes development and optimization for biotechnology production-monoclonal antibodies, in Bioseparation and Bioprocessing. A Handbook, ed by Subramanian G. Wiley-VCH, 2. Auflage (2007).
12. Ghorpade A, New trends in pharmaceutical manufacturing waste treatment. Swiss Pharma, 11a: 31-35 (2003).
13. Hagel L, Jagschies G and Sofer G, Handbook of Process Chromatographie. Elsevier/Academic Press (2008).
14. Grote F, Ditz R and Strube J, Integrierte Bioprozessentwicklung-downstream of downstream processing, Chemie Ingenieur Technik 80: 1312-1313 (2008).
15. Grote F, Ditz R and Strube J, Downstream of downstream processing-integrated bioprocess development from upstream to downstream. Chemie Ingenieur Technik 81: 1276-1277 (2009).
16. Shadle P, Erickson J, Scott R and Smith T, Antibody Purification, International Patent Classification 6: B01D 15/08 International Publication Number: WO95/22389, Applicant: Smithkline Beecham Corporation (1985).
17. Petrides D, Koulouris A and Lagonikos P, The role of process simulation in pharmaceutical process development and product commercialization. Pharmaceut Eng 22: 1-8 (2002).
18. Petrides D, Bioprocess design and economics, in Bioseparations Science and Engineering, ed by Harrison RG. Oxford University Press, New York (2003).
19. Steffens M, Fraga E and Bogle I, Synthesis of bioprocesses using physical properties data. Biotechnol Bioeng 68: 218-230 (2000).
20. Kudernatsch H, Pharma-Wasser-Ein kritischer Rohstoff in der pharmazeutischen Verwendung. Pharmind: Special Issue 8a:(2002).
21. EMA, Note for Guidance on Quality of Water for Pharmaceutical Use. 1. Juni (2002)..
22. WHO, Guidlines for Drinking Water Quality: 1 Recommendations, 3rd edn, World Health Organization, Geneva (2003).
23. Gad SC, Handbook of Pharmaceutical Biotechnology. Wiley-VCH (2007).
24. Feuerhelm K, Regelwerke zur Herstellung von Pharmawasser und Behördeninspektionen von Wassersystemen. Pharm Ind 65: 276-328 (2003).
25. Verordnung zur Novellierung der Trinkwasserverordnung vom 21. Mai (2001). DVGW,.
26. ISPE, Good Practice Guide, Commissioning and qualification of pharmaceutical water steam systems. International Society for Pharmaceutical Engineering (2007).
27. FDA, Guide to Inspections of High Purity Water Systems, (2004).
28. European Pharmacopoeia 6.0 (2008).
29. US Pharmacopoeia 33 NF 28.
30. Bendlin H, Herstellung von Pharmawasser, Good Engineering Practice, T. Berger, Verlag, Editio Cantor; 1, Aufl. (2006).
31. Hall NA, Control of pharmaceuticals, in Encyclopedia of Pharmaceutical Technology, Vol. 4 Informa Healthcare, Marcel Dekker Inc., New York (2006).
32. Japanese Pharmacopoeia, 14th edn..
33. Cross J and Wood L, Purifying water for biotechnology: a case study. Process Biochem 29: 449-453 (1994).
34. Bevilacqua AC, International standards for pharmaceutical waters. Elga News May (2005).
35. Heinzle E and Biwer A, Prozesssimulation zur frühen ökologischen Bewertung biotechnologischer Prozesse. Chemie Ingenieur Technik 73: 1467-1472 (2001).
36. Biwer A and Heinzle E, Biotechnologie als interdisziplinäre Herausforderung. Spektrum Verlag, Heidelberg (2001).
37. Biwer A, Simulation und ökologische Bewertung in der Entwicklung biotechnologischer Prozesse. Modellbildung (2003).
38. Jagschies G, Grönberg A, Björkman T, Lacki K and Hohannson H, Technical and economical evaluation of downstream processing options for monoclonal antibody production. Supplement to Biopharm International June:10-19 (2006).
39. Kelley B, Very large scale monoclonal antibody purification: the case conventional unit operations. Biotechnol Prog 23: 995-1008 (2007).
40. Barnoon BI and Bader B, Life cost analysis for single-use systems. Biopharm Int November (2008).
41. Cavagnaro JA, Preclinical Safety Evaluation of Biopharmaceuticals. Wiley & Sons, Hoboken, NJ (2008).
42. st Century-A Risk-based Approach. Final Report (2004)..
43. Guidance for Industry, Quality Systems Approach to Pharmaceutical cGMP Regulations (2006)..
44. Lewis RM, Demonstration of Comparability of a Licensed Product after a Manufacturing Change. Wiley & Sons (2008).
45. FDA Guidance Concerning Demonstration on Comparability of Human Biological Products, including Therapeutic Biotechnology-derived Products (1996)..
46. Comparability of Biotechnological Products Subjects to Change in their Manufacturing Process, Q5E (2005)..
47. Guidline on Similar Biological Medicine Products (2005)..
48. Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substances: Quality Issues (2006)..
49. Low D, O'Leary R and Pujar N, Future of antibody purification. J Chromatogr B 848: 48-63 (2007).
50. Process Analytical Technologies Initiative (2008)..
51. Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance (2004)..
52. Wilhelm S, Wasseraufbereitung. 7. Auflage, Springer, Berlin (2008).
53. Virkutyte J, Varma RS and Jegatheesan V, Treatment of Micropollutants in Water and Wastewater. IWA Publishing, London, New York (2010).
54. Deibele L and Dohrn R, Miniplant-technik, in Prozessindustrie. Wiley-VCH, Auflage 1. Auflage (2006).
55. Grote F, Fröhlich H and Strube J, Integration of ultrafiltration unit operations in biotechnology process design. Chem Eng Technol 34: 673-687 (2011).
56. Darnon E, Belleville MP and Rios GM, Modeling ultrafiltration of complex biological solutions. AIChE J 48: 1727-1736 (2002).
57. Griffiths RW and Gleich GJ, Proteolytic degradation of IgD and its relation to molecular conformation. J. Biol Chem 247: 4543-4548 (1972).
58. Grote F, Fröhlich H and Strube J, Integration of reverse osmosis unit operations in biotechnology process design. Chem Eng Technol submitted (2011).
59. Melin T and Rautenbach R, Membranverfahren, in Grundlagen der Modul- und Anlagenauslegung. Springer, Heidelberg (2007).
60. Jezowsla A, Schipolowski T and Wozny G, Reduction of random and systematic errors of test cell measurement. Desalination 200: 160-162 (2006).
61. Meier-Haack J, Untersuchung zum Einfluss von Membranmodifizierung auf das Fouling unter der Berücksichtigung des "critical flux". Newsletter SIMA-Tec 3: 1-5 (2007).
62. Jezowsla A, Schipolowski T and Wozny G, Influence of simple pre-treatment methods on properties of membrane material. Desalination 189: 43-52 (2006).
63. Mänttäri M, Pihlajamäki A, Kaipainen E and Nyström M, Effect of temperature and membrane pre-treatment by pressure on the filtration properties of nanofiltration membranes. Desalination 145: 81-86 (2002).
64. Mänttäri M, Nuortila-Jokinen J and Nyström M, Evaluation of nanofiltration membranes for filtration of paper mill total effluent. Filtr Sep 34: 275-280 (1997).
65. Costa AR, Fane AG and Wiley DE, Ultrafiltration of whey protein solutions in spacer-filled flat channels. J Membr Sci 76: 245-254 (1993).
66. Schmid RD, Taschenatlas der Biotechnologie und Gentechnik. Wiley-VCH Verlag, Weinheim, 2, Auflage (2002).
67. Ladisch M and Kohlmann K, Recombinant human insulin. Biotechnol Prog 8: 469-478 (1992).
68. Barfoed H, Insulin production technology. Chem Eng Prog 83: 49-54 (1987).
69. Klyushnichenko V, Bruch R, Bulychev A, Ditsch A, Pernenkil L and Tao F, Feasibility of international technology transfer for the production of recombinant human insulin. Bioprocess Int 8: 48-59 (2004).
70. Degermann M, Jakobsson N and Nilson B, Modeling and optimization of preparative reversed-phase liquid chromatography for insulin purification. J Chromatogr A 1162: 41-49 (2007).
71. Zündorf I and Dingermann T, Vom Rinder-, Schweine-, Pferde-Insulin zum Humaninsulin: Die biotechnische und gentechnische Insulin-Herstellung, Pharmazie in unserer zeit Nr. 1, 30:(2001).
72. Kroeff E, Owens R, Campbell E, Johnson R and Marks H, Production scale purification of biosynthetic human insulin by reversed phase high performance liquid chromatography. J Chromatogr 461: 45-61 (1984).
73. Heinzle E, Biwer A and Cooney C, Development of Sustainable Bioprocesses. Wiley-VCH Verlag, Weinheim, 1. Auflage (2006).
74. Lowe D, Antibiotics, in Basic Biotechnology. Cambridge University Press, Cambridge, 349-375 (2001).
75. Ohno M, Otsuka M, Yagisawa M, Kondo S, Hoffmann H, Sakutsch D, et al, Ullmann's Encyclopedia of Industrial Chemistry. Wiley.VCH Verlag, Weinheim (2002).
76. Perry R, Green D and Maloney J, Perry's Chemical Engineers' Handbook. McGraw-Hill, New York (1997).
77. Strohl W, Biotechnology of Antibiotics. Marcel Dekker, New York (1997).
78. Chang Z, Wie X and Chen J, Simulated foam separation of butyl acetate from wastewater discharged by solvent extraction operation in penicillin production. Sep Sci Technol 37: 981-991 (2002).